Zantac, an antacid medication that has been on the market since 1983, is now suspected of causing several different kinds of cancer, including stomach, bladder, kidney, pancreatic, esophageal, intestinal, liver, uterine, testicular and colon cancers. On April 1, 2020 the U.S. Food and Drug Administration (“FDA”) called for the immediate removal of Zantac, and its generic form, Ranitidine, from the consumer market.
The concern connecting Zantac and cancer diagnosis stems from unacceptable contamination levels of N-Nitrosodimethylamine, or NDMA, a chemical that may cause cancer. The FDA’s recent findings suggest that the levels of this cancer chemical can increase over time and when stored at higher than room temperature levels.
Recently filed lawsuits allege that the manufacturers of Zantac, and associated medications, knew that the drugs could form NDMA in the human body and increase the risk for cancer, but failed to inform consumers of this risk.
Within five years of coming onto the market, Zantac was the world’s bestselling drug, earning over $1 billion dollars in annual sales. As recently as 2018, nearly 25 million prescriptions were written annually for this highly profitable drug. The number of people affected by the carcinogens in Zantac is extensive.
If you or a loved one have been diagnosed with cancer and had taken Zantac or Ranitidine, either by prescription or over-the-counter, you may be entitled to compensation. Contact Geiser, Bowman & McLafferty, LLC for your free case evaluation. There is no attorney fee unless we recover financial compensation for you.